Leadership Team
A highly experienced team with a strong track record of performance
The ImmVirX team comprises key directors and the executive and scientific staff from Viralytics, a clinical-stage oncolytic immunotherapy company acquired in June 2018 by Merck and Co. Inc. for A$502 million.
Management Team
In the News
View our recent news stories
Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.
View All Stories
ImmVirX Poster Presentations on Preclinical and Clinical Programs at AACR Annual Meeting, Chicago
March 27, 2025
No Comments
Read More »
First patients dosed in Phase 1b combination study in colorectal, gastric and ovarian cancer
October 28, 2024
No Comments
Read More »
